35% increase in survival rates for a preclinical combination model is not going to excite the market in this environment.
Needs strong Phase 2 data to move the needle.
Its all about timing your entry in binary biotechs.
35% increase in survival rates for a preclinical combination...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
0.004(4.21%) |
Mkt cap ! $27.47M | |||
| Open | High | Low | Value | Volume |
| 9.5¢ | 10.0¢ | 9.5¢ | $122.4K | 1.247M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 80783 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 121458 | 4 |
View Market Depth
| Last trade - 13.46pm 05/09/2024 (20 minute delay) ? |
| ATX (ASX) Chart |